Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 28, 2005

View Archived Issues

IDO - a target for anti-HIV therapy

H-1152: superior bronchodilatory potency and suggested safety for anesthesia in asthmatics

Further evidence that TRPV1 antagonism alleviates bone cancer pain

Enrollment completed in phase IIb HCV study of Albuferon plus ribavirin

ID Biomedical updates progress of two key vaccine programs

Idera studies HYB-2055 in combination with gemcitabine and carboplatin

Encouraging results for QR-442 in multiple sclerosis mouse model

Cerimon acquires U.S. rights to topical diclofenac formulations

Bayer and Ortho-McNeil enter agreement for BAY-59-7939

AT-1001 completes phase I study, receives fast track designation

Chiron begins phase I/II study of cell culture-derived influenza vaccine

Indevus begins phase III of PRO-2000 to prevent STDs

Novelos Therapeutics to hold end-of-phase II meeting for NOV-002

Vion offers pipeline progress report

JNJ-7706621 possesses dual inhibitory activity against CDKs and Aurora kinases

Immunomodulatory agents described in Novartis patents

Novel inhibitor of sphingolipid synthesis opens a new approach for anti-HCV drug design

Recent patents disclose novel agents for the treatment of diabetes

New agents claimed for the treatment of metabolic disorders

Aptivus for HIV receives European approval

Xolair approved in Europe

Noxafil approved in E.U. for invasive fungal infections

TNX-355 reported effective in reducing viral load of HIV-infected patients

Update on pimecrolimus in the treatment of skin disorders

Studies highlight antidepressant efficacy and other benefits of agomelatine

Study reveals how adiponectin may influence survival and longevity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...